Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

Though there are very few characters in MASH who aren't beloved by audiences and critics, these individuals rise to the top ...

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

This local sensation mashes up pop and rock hits with a full brass section, turning every show into a high-energy singalong.

Making crispy fries at home can be quite an effort. Meanwhile, delicious potato balls always turn out soft on the inside and ...